Introduction
Despite the recent approval of a long-acting triamcinolone intraarticular injection preparation for the treatment of knee osteoarthritis (OA), the development of new effective pharmacologic treatments, particularly structuremodifying ones, for this common disabling disease, remains a great source of frustration. Studies of joint biology and clinical studies using magnetic resonance imaging (MRI) have identified numerous structural and molecular treatment targets that offer promise in terms of alleviating pain and slowing disease progression in OA, yet none of these is at the cusp of generating new approved therapies that would either modify the disease process or relieve OA joint pain. There could be new treatments that specifically focus on pain sensitization or other biologic factors that contribute to pain. Modifying the mechanopathology of OA, which is better understood than in the past, could also provide new opportunities for OA treatment.
With a focus on trial design and methods, the goal of this article is to explore reasons that treatment development in OA has been so slow and has remained behind treatment advances in other rheumatic diseases. While the suggested changes in the methodology or approach to trials may not yield results any different from previous ones, we will make the case that changes in approaches to evaluating efficacy will increase the chances of demonstrating efficacy of promising treatments for OA. These might include therapies that are already under evaluation, are currently being used for other diseases, or are under development.
The challenge of treatment development in OA is formidable for at least two reasons. First, OA pathogenesis combines mechanopathology and the biologic response to mechanically induced injury, which appear to act synergistically in causing both joint damage and pain. Treatment may fail in some patients if one or the other of these critical causal elements is not addressed. Second, the relationship between pain relief and structural improvement is not linear. In some instances, pain relief may lead to structural worsening, creating an additional challenge with regard to treatments whose goals are to improve both. Thus, while we will suggest changes in the approach to treatment development, even the changes that we suggest may be insufficient. While therapeutic advances may be possible now, especially with our better understanding of causes of both pain and joint damage, progress will still not come easily.
The impact and challenges of OA are enormous. OA is the most common form of arthritis, and its ranking in the global burden of disease has been increasing year by year (1) with aging of populations throughout the world and increasing rates of obesity. Rates of total knee replacement have been rising exponentially in the US, with projected numbers of knee replacements in the year 2030 exceeding 3 million annually, from the current rate of just over 700,000 per year (2) . This high rate of knee replacements can be ascribed in large part to the inadequacy of nonsurgical treatments with respect to pain relief, long-term adherence, and delay of disease progression. Development of treatments that relieve pain and delay the need for knee replacement is a high priority in clinical practice and in the public health arena.
Before even embarking on human trials of new therapies, decision-making about which compounds to move forward to human trials can be fraught. For example, preclinical models chosen for testing may not necessarily be ideal for adequately reflecting efficacy in human OA. Potentially promising compounds may not advance because of toxicity issues despite promising efficacy signals, and additional work to modify compounds to optimize the efficacy:safety signal may not be pursued.
The challenges in studying treatments that relieve OA pain versus those that may delay structural worsening are different, with the latter being more problematic. We will indicate below which of these challenges are being addressed. While our suggestions relate clearly to pharmacologic and biologic agents to be developed, they are also relevant to interventions that focus on joint loading such as weight loss, devices, and even exercise, though we acknowledge that trials of nonpharmacologic interventions have their own additional challenges, often including poor adherence to long-term treatment. While examples will be drawn from knee OA trials, the issues identified can be generalized to OA in all joints studied so far.
Challenges for trials evaluating effects of treatments on pain in OA Primary pain outcome measures in trials. In OA trials, participants usually respond to a survey about pain that constitutes the trial's primary outcome measure. In addition, a variety of information is collected from patients in survey form but not generally incorporated into the primary outcome measure, even though the findings from these other measures are correlated with that outcome. When pain assessed according to the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) (3) is the primary outcome measure, other measures assessed typically include WOMAC stiffness and physical function, and even the frequency of rescue medication use.
In rheumatoid arthritis (RA) and in cardiovascular disease, composite outcome measures have been created to take advantage of the fact that disease improvement is often reflected in multiple related ways and that combining data from correlated outcomes improves the sensitivity of instruments in detecting treatment effects. While there is a hint of this effect in OA trials, it is difficult to discern in individual trials given the high correlation between WOMAC pain and other outcomes. Recent evidence (4) suggests that a composite outcome measure combining all WOMAC scales and rescue medication is more sensitive to change than use of WOMAC pain alone. The Outcome Measures in Rheumatology group effort in identifying relevant domains and instruments to assess those domains may be a first step toward developing a composite outcome measure for OA trials. As in RA and cardiovascular diseases, the focus on a composite outcome measure should be accompanied by presentation of results for individual outcomes that contribute to the composite, to promote greater understanding of the intervention's specific effects (e.g., pain, function, etc.).
Further, use of the pain subscale of the WOMAC as the primary outcome measure in trials may not allow for optimal sensitivity to change (5) . The WOMAC pain scale sums patient-reported pain during 5 selected activities, including especially walking and stair climbing. For some patients, pain may improve with activities not captured by the WOMAC (and therefore not detected as effects of treatment) and the wording of the WOMAC pain questions (e.g., how do individuals answer a question about pain going up or down stairs if they have pain descending but not going up stairs, or if they do not climb any stairs?). Last, for interventions targeting specific knee problems (such as knee bracing for patellofemoral disease), a survey that includes activity-related pain of questionable relevance (pain on standing) may not be sensitive to treatment effects (5) .
Another problem with using pain as an outcome measure is that in some patients, improvement in OA symptoms may be accompanied not by a reduction in pain but rather by an improvement in their ability to do particular activities, leading to increased activity levels. Patients may not report a change in pain severity but may become more active with the same level of pain. Incorporating measures of activity into the assessment of pain, as has been suggested by Lo et al (6) , might enhance the sensitivity of detecting change in OA so as to make it easier to detect treatment effects.
FELSON AND NEOGI
The multiple causes of pain in OA. One challenge in targeting pain in OA is that pain itself is multifactorial. Treatments targeting a single mechanism of pain may be insufficient to deliver a large treatment effect if that mechanism is not operational in the majority of patients. Joint replacement surgery does relieve pain in almost everyone with disease, but at the cost of the removal of all joint tissues that may generate pain. Pharmacologic therapies do not target "the whole joint." Further, the residual joint pain after knee replacement in 20-30% of patients may suggest that pain mechanisms not addressed by arthrectomy persist. A one-size-fits-all approach to pain treatment is unlikely to address all sources of pain given the numerous contributors to pain beyond structural disease, including psychological factors and pain sensitization. By extension, for clinical trials the best prediction of treatment response for pain outcome measures may require stratification by psychological characteristics (7) .
Identifying particular pain mechanisms may improve the ability to detect treatment response and identify patients who are most likely to benefit from treatment. For example, while in a trial setting intraarticular botulinum toxin demonstrated no benefit compared to placebo in the overall sample, there was significant pain improvement in subjects with nociceptive pain, but not in those with neuropathic or uncertain mechanisms of pain (8) . Including a heterogeneous sample of patients in trials may mask differential benefit in a particular subgroup. In another proof-of-concept application of pain phenotyping and stratification of treatment, conditioned pain modulation, which reflects adequacy of descending inhibitory modulation in the central nervous system, predicted efficacy of duloxetine for treatment of diabetic neuropathy (9) . In contrast, excluding individuals with widespread pain may enable signal detection, as suggested in a post hoc analysis of findings in a phase II trial of the Wnt pathway inhibitor SM04690 (10) . These types of approaches need to be formally tested in larger well-conducted trials to fully determine their utility. Nonetheless, understanding which pathways are operational in an individual's pain experience may aid in targeting appropriate therapy.
However, there is a theoretical risk of structural damage with the use of a treatment targeting nociceptive pain relief alone without addressing appropriate joint protection. Thus, for therapies that target certain pain mechanisms, there remains the challenge of assuring that necessary nociception remains intact. For treatments primarily targeting structure, there is a yet-to-be-proven theoretical expectation that there may be a downstream pain benefit associated with less structural progression. Whether such treatments are clinically useful if there is no pain benefit is unclear. These issues raise the philosophical question of whether management of OA can realistically be attained with a single treatment or whether it will require multiple treatments, targeting relevant facets of pain, structure, and biomechanics as appropriate for each individual.
Underpowered trials. It is natural for investigators who are planning a trial and are enthusiastic about the new treatment being tested to anticipate that this treatment is likely to be highly effective. Unfortunately, treatments in OA are generally only moderately effective with respect to pain relief. For example, a meta-analysis of the effect of intraarticular steroids on pain in knee OA revealed an effect size of 0.33 (one-third of the standard deviation) (11) . This compares to effect sizes of~0.6-1.2 for methotrexate in RA (12) . Indeed, for many years Brandt et al (13) suggested that nonsteroidal antiinflammatory drugs (NSAIDs) were no more effective than acetaminophen in the treatment of OA, based on one trial in which there actually was superiority of NSAIDs (14) , but the effect was modest and failed to reach significance. Subsequent meta-analyses of trials comparing NSAIDs versus acetaminophen have definitively shown that NSAIDs are more efficacious but that this effect is modest, with an effect size of~0.3 (15) . Expecting large treatment effects in OA is probably unreasonable, and trials designed with that expectation will often fail to demonstrate treatment effects when such effects exist. Unfortunately, sample size requirements expand when small treatment effects are sought, making trials more challenging and expensive.
While single centers may be prone to underpower studies given a potentially limited pool of eligible subjects, even large pharmaceutical company efforts have anticipated unrealistically high treatment effects. For example, a major phase II trial of tanezumab for OA pain (16) estimated an effect size of 0.5 for pain. The good news was that for this treatment at high doses the effect size was actually greater, but other phase III trials of nerve growth factor (NGF) inhibitors using lower doses have shown a more typical effect size of 0.3-0.4 for pain (17) , suggesting that if this treatment had been tested only at low doses, pain effects would likely have been missed.
Challenges for trials targeting structural changes in OA
Joint space loss as an outcome measure. An important aspect of trial design for treatments targeting structure is identifying the appropriate primary structural outcome measure. There has been an excessive focus on joint space loss, primarily because the Food and Drug Administration (FDA) in the US has, until recently, required delay of joint space loss in knee and hip OA as evidence that a treatment has a structure-modifying effect. The recent white paper "Osteoarthritis: A Serious Disease" (18) , submitted to the FDA in December 2016 (18) , aims to support a pathway that establishes the importance of OA as a serious condition according to the FDA definition, for which there are currently no satisfactory therapies-thereby lessening the regulatory reliance on joint space loss alone.
There is already a large body of literature debating the pros and cons of this focus on radiographically assessed joint space (e.g., ref. 19 ), but as investigators involved in multiple longitudinal studies in which radiographic joint space loss has been utilized as a structural outcome measure, we are aware of its many foibles. First, medial joint space loss is reversed in patients with lateral joint disease, so that pseudowidening, rather than narrowing, occurs. Second, our group has demonstrated that meniscal extrusion and meniscal disease per se can cause joint space loss without cartilage disease (20, 21) , although the two usually coexist. Third, in severe disease, bone attrition and other bone shape alterations occur, which can, over time, alter apparent joint space as seen on radiographs. Attrition has been demonstrated on MRI in non-end-stage disease and its effect on joint space width is unknown, but could make it impossible to determine structure-modifying efficacy if the latter is defined as preservation of the joint space. Finally, joint space loss based on radiography is seen in 2 dimensions, and 3-dimensional assessments either by computed tomography scanning (22) or by MRI (19) are more sensitive to change. The focus on preservation of joint space as a primary outcome measure may have prevented the identification of treatments that might have delayed disease progression, such as risedronate (23) and inducible nitric oxide synthase (iNOS) inhibitors (24) .
Cartilage loss as an outcome measure. Even if we jettison radiographic joint space loss as the measure of structural deterioration, there remain important questions about whether cartilage loss should be used as a primary structural outcome measure in OA. First, healthy cartilage is not innervated and may not be a major source of pain. Pain is by far the predominant concern that drives patients to seek care. The correlation between cartilage loss and pain is modest (25) (26) (27) , and some studies have shown no association at all (28, 29) . Further, there is no evidence to date that any treatment that delays cartilage loss without also affecting other joint pathology in OA has a favorable effect on pain.
What effect might relieving pain, especially alleviating so-called nociceptive pain, have on cartilage? Ablating nociceptive pain could lead to joint deterioration and cartilage loss. After all, pain has both favorable and unfavorable effects. It can modify the way a person walks, so as to minimize joint stress and ultimately joint damage. This was demonstrated by Schnitzer et al (30) , who showed that in patients with painful medial knee OA, pain reduction with NSAIDs led to an increase in the knee adduction moment (a measure of medial loading). This suggests that pain reduction would lead individuals to increase their medial load and likely damage the medial joint. Recent studies of NGF inhibitor treatment in OA patients with prior joint damage have suggested that rapid deterioration of OA occurs in a subset of patients (31), particularly when an NGF inhibitor is given in combination with NSAIDs. While there are ongoing investigations into potential biologic mechanisms, this may also be due, in part, to the same phenomenon noted by Schnitzer and colleagues (30) , that effective ablation of pain may lead to either activities or ways of walking that cause damage to the joint. In addition, in a randomized trial of indomethacin versus azapropazone treatment of hip OA, use of the more effective pain reliever, indomethacin, led to earlier joint replacement and more cartilage loss (32) . It is ultimately not clear whether pain relief per se can be accompanied by delay in structural progression or whether any effective pain reliever in OA is naturally going to be accompanied by structural deterioration.
Nonetheless, there are efforts to develop structure-modifying treatments that target cartilage, with an aim to demonstrate an initial effect of reducing cartilage loss followed later by improvement in pain. This assumes that protecting against cartilage loss in the affected compartment of knees with OA is achievable and will ultimately relieve pain-both of which are unproven. First, while trials have shown local stabilizing effects on cartilage, these have been primarily in the nondiseased and nonloaded lateral knee compartment in patients with medial knee OA (33, 34) . Second, attempting to demonstrate a symptom benefit downstream from cartilage preservation has the added challenge of the feasibility of conducting a trial over several years while maintaining blinding and adherence and minimizing loss to follow-up. It also would require maintaining placebo treatment in some participants for several years. Last, this strategy begs the question of whether an OA treatment that has no effect on reducing pain for up to 3 years will be welcomed by patients and their physicians.
Alternative approaches to structure modification include a focus on innervated structures in the OA joint including bone and synovium, in which pathology includes bone marrow lesions and synovitis, respectively. Studies have shown that both predict subsequent cartilage loss or structural deterioration (35, 36) . There is also strong evidence that each of them causes pain and that bone marrow lesion and synovial tissue volumes seen on MRI fluctuate in parallel with pain 1178 FELSON AND NEOGI (37, 38) . Recent proof-of-concept trials have demonstrated the potential for targeting bone marrow lesions with accompanying symptom relief, though longer-term outcomes are not known (39, 40) . Should rapid progressors be the focus? Given the desire to identify structure-modifying drugs for OA, there has been a recent focus on identifying persons with OA who are at high risk of cartilage loss, so as to select trial subjects who are likely to experience the outcome of interest in a short period of time. There are several major limitations to this approach. First, while OA is highly prevalent, recruiting patients for trials is challenging, and imposing additional restrictions to identify those at high risk of progression may make recruitment even more difficult. The second and probably more salient concern is that for many years, studies have shown that those with the highest risk of rapid progression are those with advanced structural disease (41) . Specifically, knees with Kellgren/Lawrence grade 3 OA (0-4 scale) (42) have a much higher risk of radiographic progression than those with less severe OA. Grade 3 OA is accompanied by considerable cartilage loss and often malalignment, two factors that can lead to ineluctable disease progression, which may not be treatable. Indeed, recent attempts to develop an iNOS inhibitor for OA (24) suggested that while patients with Kellgren/Lawrence grade 3 disease experienced progression at a much higher rate than those with grade 2 disease, the therapeutic effect of this inhibitor was not seen in knees with grade 3 disease; rather, there was a delay in joint space loss in knees with grade 2 disease. Thus, selection of subjects at higher risk of progression may actually work against selecting patients or knees whose disease progression is preventable with biologic agents. This example also may suggest the likelihood of treatment failure when pharmacologic approaches are used alone in late-stage OA, where potent adverse biomechanical factors contribute to joint destruction.
Because patients with advanced disease tend to experience more rapid structural progression (i.e., cartilage loss) than those without advanced disease, finding indicators or biomarkers of rapid progression does not necessarily increase the likelihood of success. These markers would be identifying persons whose disease is so advanced that they are unlikely to respond to biologically targeted agents.
Challenges for trials targeting either pain or structure: opportunities in stratified medicine and new trial designs Testing stratified medicine approaches. There is an increasing body of literature suggesting that OA is not one disease but rather consists of subgroups of patients, each representing a different disease pathogenesis. Each of these phenotypes, such as inflammatory OA or OA driven by mechanopathology, invokes distinct treatment approaches. While this concept is intuitively appealing, proof will come when trials demonstrate that patients with a particular phenotype respond differently to a treatment than those without that phenotype. This has been demonstrated, for example, in randomized trials in patients with lung cancer with an epidermal growth factor receptor mutation (43) and was recently demonstrated for eosinophilic chronic obstructive pulmonary disease (44) . One reason for failure to develop OA treatments may be that a given therapy may not be effective for all persons with the disease, and treatment strategies may require defining a phenotype likely to respond to a specific treatment, which may not be effective for those with a different phenotype. Despite multiple efforts to define phenotypes for OA, there is a paucity of trials testing this approach. For example, knee OA patients with severe malalignment or morbid obesity are not likely to experience benefit from a cartilage anabolic agent. While trials often exclude such patients, the hostile mechanical environment in many OA joints (as evidenced by, e.g., dynamic malalignment or meniscal maceration) may preclude their response to such treatments when they are included in a trial. Even treatments targeting the aberrant mechanics of knee OA may fail if the phenotype of treated patients includes those with inflammatory subtypes.
New trial designs. A related concern is the paucity of trials that have incorporated new approaches to trial design that might make treatment testing more efficient. Adaptive trial designs have been developed in part to allow not only for testing of novel therapies, but also for testing whether specific subgroups of patients are likely to respond better to a given treatment than others (45) . We are aware of only one adaptive trial in OA (46) , and this did not examine subgroups. Among adaptive trials, enrichment designs might be especially efficient in identifying phenotypes. In these designs, initial testing of a therapy in several subgroups is followed by interim analyses after which only subgroups experiencing treatment benefit are randomized, and subgroups showing no treatment effect are withdrawn from the trial. Enrichment designs could be used to identify subsets of patients (e.g., those with an inflammatory phenotype) who respond to a given treatment or could be used to move from a phase II trial testing different doses of a treatment to a phase III trial in which the doses that did not show efficacy were dropped and patients who had been randomized as part of phase II were included in the phase III results. Another approach that offers promise is the more widespread use of a crossover design (for pain effects or effects on structures where pathology waxes and wanes, such as bone marrow lesions)-a design that enhances the power to detect modest treatment effects. Also related to trial design are unrealistic expectations about treatment efficacy as noted above, so that trials in which smaller treatment effects are anticipated are more likely to be successful in detecting efficacy.
Conclusions
Ultimately, many questions related to the methodology of trials in OA and the approach to the disease itself need to be addressed if new exciting therapies are to show efficacy and obtain regulatory approval for the treatment of this disease. Certainly our improved understanding of the biology of OA including findings from animal studies, and our better recognition of sources of pain, are increasingly making available ideas that support new treatment options in OA. For those to be realized, new approaches to trial design and outcome measures must be tested.
